Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Up – Here’s What Happened

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shares gapped up before the market opened on Tuesday . The stock had previously closed at $30.29, but opened at $31.70. Supernus Pharmaceuticals shares last traded at $30.71, with a volume of 27,147 shares changing hands.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on SUPN. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 17th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Up 1.1 %

The firm has a market cap of $1.71 billion, a price-to-earnings ratio of 28.61 and a beta of 0.90. The company’s 50-day moving average price is $32.59 and its 200-day moving average price is $35.04.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, SVP Jonathan Rubin sold 927 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 700 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,103.38. This represents a 6.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock worth $440,263 in the last three months. 9.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Raiffeisen Bank International AG acquired a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $25,000. Financial Management Professionals Inc. acquired a new position in shares of Supernus Pharmaceuticals during the 1st quarter worth $30,000. Versant Capital Management Inc lifted its holdings in shares of Supernus Pharmaceuticals by 6,931.3% in the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company’s stock valued at $37,000 after purchasing an additional 1,109 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Supernus Pharmaceuticals in the 4th quarter valued at approximately $42,000. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 870 shares during the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.